[HTML][HTML] Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
D Planchard, PA Jänne, Y Cheng… - … England Journal of …, 2023 - Mass Medical Soc
Background Osimertinib is a third-generation epidermal growth factor receptor–tyrosine
kinase inhibitor (EGFR-TKI) that is selective for EGFR-TKI–sensitizing and EGFR T790M …
kinase inhibitor (EGFR-TKI) that is selective for EGFR-TKI–sensitizing and EGFR T790M …
Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer
VD de Jager, W Timens, A Bayle, J Botling… - The Lancet Regional …, 2024 - thelancet.com
For patients with advanced stage non-small cell lung cancer (NSCLC), treatment strategies
have changed significantly due to the introduction of targeted therapies and immunotherapy …
have changed significantly due to the introduction of targeted therapies and immunotherapy …
Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
LE Hendriks, KM Kerr, J Menis, TS Mok… - Annals of …, 2023 - annalsofoncology.org
Diagnosis of tumour type allows prognostication and triage for biomarker testing (see the
Supplementary Material Section 3 and Supplementary Figure S1, available at https://doi …
Supplementary Material Section 3 and Supplementary Figure S1, available at https://doi …
Challenges and controversies in resectable non-small cell lung cancer: a clinician's perspective
I Houda, C Dickhoff, CA Uyl-de Groot… - The Lancet Regional …, 2024 - thelancet.com
The treatment landscape of resectable early-stage non-small cell lung cancer (NSCLC) is
transforming due to the approval of novel adjuvant and neoadjuvant systemic treatments …
transforming due to the approval of novel adjuvant and neoadjuvant systemic treatments …
[HTML][HTML] Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from …
A Passaro, J Wang, Y Wang, SH Lee, B Melosky… - Annals of …, 2024 - Elsevier
Background Amivantamab plus carboplatin–pemetrexed (chemotherapy) with and without
lazertinib demonstrated antitumor activity in patients with refractory epidermal growth factor …
lazertinib demonstrated antitumor activity in patients with refractory epidermal growth factor …
HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor–mutated non–small-cell lung cancer after epidermal …
HA Yu, Y Goto, H Hayashi, E Felip… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE Patritumab deruxtecan, or HER3-DXd, is an antibody-drug conjugate consisting
of a fully human monoclonal antibody to human epidermal growth factor receptor 3 (HER3) …
of a fully human monoclonal antibody to human epidermal growth factor receptor 3 (HER3) …
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; …
JE Gray, MJ Ahn, GR Oxnard, FA Shepherd… - Clinical cancer …, 2023 - AACR
Purpose: Plasma circulating tumor DNA (ctDNA) analysis is used for genotyping advanced
non–small cell lung cancer (NSCLC); monitoring dynamic ctDNA changes may be used to …
non–small cell lung cancer (NSCLC); monitoring dynamic ctDNA changes may be used to …
CNS efficacy of osimertinib with or without chemotherapy in epidermal growth factor receptor–mutated advanced non–small-cell lung cancer
PA Jänne, D Planchard, K Kobayashi… - Journal of Clinical …, 2024 - ascopubs.org
PURPOSE We report CNS efficacy of first-line osimertinib plus chemotherapy versus
osimertinib monotherapy in patients with epidermal growth factor receptor (EGFR)–mutated …
osimertinib monotherapy in patients with epidermal growth factor receptor (EGFR)–mutated …
[HTML][HTML] Brief report: durvalumab after chemoradiotherapy in unresectable stage III EGFR-mutant NSCLC: a post hoc subgroup analysis from PACIFIC
Introduction Consolidation durvalumab (the “PACIFIC regimen”) is standard of care for
patients with unresectable stage III NSCLC who have not progressed after …
patients with unresectable stage III NSCLC who have not progressed after …
[HTML][HTML] Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for …
Background We evaluated whether tissue tumor mutational burden (tTMB) and STK11,
KEAP1, and KRAS mutations have clinical utility as biomarkers for pembrolizumab …
KEAP1, and KRAS mutations have clinical utility as biomarkers for pembrolizumab …